AU5788800A - Peptide boronic acid inhibitors of hepatitis c virus protease - Google Patents

Peptide boronic acid inhibitors of hepatitis c virus protease

Info

Publication number
AU5788800A
AU5788800A AU57888/00A AU5788800A AU5788800A AU 5788800 A AU5788800 A AU 5788800A AU 57888/00 A AU57888/00 A AU 57888/00A AU 5788800 A AU5788800 A AU 5788800A AU 5788800 A AU5788800 A AU 5788800A
Authority
AU
Australia
Prior art keywords
hepatitis
boronic acid
acid inhibitors
virus protease
peptide boronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU57888/00A
Inventor
Timothy Patrick Forsyth
Sharada Jagannathan
Charles A. Kettner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of AU5788800A publication Critical patent/AU5788800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU57888/00A 1999-07-07 2000-07-07 Peptide boronic acid inhibitors of hepatitis c virus protease Abandoned AU5788800A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14256199P 1999-07-07 1999-07-07
US60142561 1999-07-07
PCT/US2000/018655 WO2001002424A2 (en) 1999-07-07 2000-07-07 Peptide boronic acid inhibitors of hepatitis c virus protease

Publications (1)

Publication Number Publication Date
AU5788800A true AU5788800A (en) 2001-01-22

Family

ID=22500325

Family Applications (2)

Application Number Title Priority Date Filing Date
AU59204/00A Abandoned AU5920400A (en) 1999-07-07 2000-07-07 Cell-based assay systems for examining hcv ns3 protease activity
AU57888/00A Abandoned AU5788800A (en) 1999-07-07 2000-07-07 Peptide boronic acid inhibitors of hepatitis c virus protease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU59204/00A Abandoned AU5920400A (en) 1999-07-07 2000-07-07 Cell-based assay systems for examining hcv ns3 protease activity

Country Status (4)

Country Link
EP (1) EP1196436A2 (en)
AU (2) AU5920400A (en)
CA (1) CA2376965A1 (en)
WO (2) WO2001002424A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002048116A2 (en) * 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
AU2002243508A1 (en) 2001-01-10 2002-07-24 Bristol-Myers Squibb Company Patent Department Alpha-aminoboronic acids prepared by novel synthetic methods
FI2251344T4 (en) 2001-01-25 2024-04-29 The United States Of America Represented By The Secretary Formulation of boronic acid compounds
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7112572B2 (en) 2002-09-09 2006-09-26 Trigen Limited Multivalent metal salts of boronic acids
DE60305113T2 (en) 2002-09-09 2006-12-07 Trigen Ltd. Boric acid salts and their use in the provision of drugs for thrombosis treatment
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
CN100453553C (en) 2003-04-11 2009-01-21 沃泰克斯药物股份有限公司 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
AU2011203054B2 (en) * 2003-04-11 2012-04-26 Vertex Pharmaceuticals, Incorporated Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
KR101115294B1 (en) 2003-05-21 2012-04-12 베링거 인겔하임 인터내셔날 게엠베하 Hepatitis C inhibitor compounds
WO2005024051A1 (en) * 2003-06-23 2005-03-17 Vanderbilt University Cell-based assay for identifying peptidase inhibitors
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
MY148123A (en) * 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EA200600498A1 (en) 2003-09-22 2006-10-27 Бёрингер Ингельхайм Интернациональ Гмбх MACROCYCLIC PEPTIDES THAT EXPRESS ANTI-VIRUS ACTIVITY AGAINST THE HEPATITIS C VIRUS
ES2358333T3 (en) 2004-01-21 2011-05-09 Boehringer Ingelheim International Gmbh MACROCYCLIC PEPTIDES WITH ACTION AGAINST THE VIRUS OF HEPATITIS C.
US7884112B2 (en) 2004-03-08 2011-02-08 Stuart Edward Bradley Pyrrolopyridine-2-carboxylic acid hydrazides
BRPI0512049A (en) 2004-06-14 2008-02-06 Anacor Pharmaceuticals Inc antiviral uses of boronic acid complexes
UY29016A1 (en) 2004-07-20 2006-02-24 Boehringer Ingelheim Int ANALOGS OF INHIBITING DIPEPTIDES OF HEPATITIS C
JP4914355B2 (en) 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Hepatitis C inhibitor peptide analog
WO2006059164A2 (en) 2004-12-02 2006-06-08 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amides
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
EP1863804A1 (en) * 2005-04-01 2007-12-12 Methylgene, Inc. Inhibitors of histone deacetylase
JP2009503084A (en) * 2005-08-01 2009-01-29 フェノミックス コーポレーション Hepatitis C serine protease inhibitor and use thereof
US7951823B2 (en) 2006-05-23 2011-05-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
WO2008070733A2 (en) * 2006-12-06 2008-06-12 Phenomix Corporation Macrocyclic hepatitis c serine protease inhibitors and uses therefor
EP2117537A1 (en) 2007-02-09 2009-11-18 Irm Llc Compounds and compositions as channel activating protease inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EA201500431A1 (en) 2008-06-17 2015-11-30 Милленниум Фармасьютикалз, Инк. COMPOUNDS OF BONONATE AIR AND ITS PHARMACEUTICAL COMPOSITIONS
AR075090A1 (en) 2008-09-29 2011-03-09 Millennium Pharm Inc ACID DERIVATIVES 1-AMINO-2-CYCLLOBUTILETILBORONICO PROTEOSOMA INHIBITORS, USEFUL AS ANTI-BANKER AGENTS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM.
JP5783659B2 (en) 2009-12-22 2015-09-24 セファロン、インク． Proteasome inhibitors and methods for their preparation, purification and use
AR080185A1 (en) * 2010-02-19 2012-03-21 Glaxo Group Ltd DERIVATIVES OF BORONIC AND BENZOFURAN ACID, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USE OF THE SAME IN THE TREATMENT AND / OR PREVENTION OF VIRAL INFECTIONS, IN PARTICULAR BY HEPATITIS C (HCV) VIRUSES.
NZ602622A (en) 2010-03-31 2015-01-30 Millennium Pharm Inc Derivatives of 1-amino-2-cyclopropylethylboronic acid
WO2012067663A1 (en) * 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
KR20140093209A (en) * 2011-08-17 2014-07-25 글락소스미스클라인 엘엘씨 Therapeutic methods
ME02588B (en) 2011-08-19 2017-06-20 Glaxo Group Ltd Benzofuran compounds for the treatment of hepatitis c virus infections
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
US20150335668A1 (en) 2014-05-20 2015-11-26 Millennium Pharmaceuticals, Inc. Method for cancer therapy
AU2015327346B2 (en) * 2014-10-01 2019-12-05 Merck Patent Gmbh Boronic acid derivatives
AU2015327345B9 (en) * 2014-10-01 2020-06-18 Merck Patent Gmbh Boronic acid derivatives
AU2015327412B2 (en) * 2014-10-01 2020-01-16 Merck Patent Gmbh Boronic acid derivatives
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
EA201990069A1 (en) 2016-06-21 2019-06-28 ОРИОН ОФТАЛМОЛОДЖИ ЭлЭлСи DERIVATIVES OF HETEROCYCLIC PROLINAMIDE
KR20230159839A (en) 2021-03-15 2023-11-22 메이즈 테라퓨틱스, 인코퍼레이티드 Inhibitors of glycogen synthase 1 (GYS1) and methods of using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599906A (en) * 1990-04-13 1997-02-04 Schering Corporation Protease assays
IT1272179B (en) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio METHODOLOGY TO REPRODUCE IN VITRO THE PROTEOLITHIC ACTIVITY OF THE NS3 PROTEASE OF THE VIRUS HCV.
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
KR100209095B1 (en) * 1996-06-28 1999-07-15 성재갑 Substitution hepatitis c virus which can be used for detecting the activity of the hcv protease, and recombinant gene and use
PL194025B1 (en) * 1996-10-18 2007-04-30 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
WO1998037180A2 (en) * 1997-02-22 1998-08-27 Abbott Laboratories Hcv fusion protease and polynucleotide encoding same
CA2294049A1 (en) * 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptides
US6280940B1 (en) * 1998-08-05 2001-08-28 Agouron Pharmaceuticals, Inc. Reporter gene system for use in cell-based assessment of inhibitors of the Hepatitis C virus protease
EP1177211B1 (en) * 1999-05-04 2008-02-20 Boehringer Ingelheim (Canada) Ltd. Surrogate cell-based system and method for assaying the activity of hepatitis c virus ns3 protease

Also Published As

Publication number Publication date
CA2376965A1 (en) 2001-01-11
AU5920400A (en) 2001-01-22
EP1196436A2 (en) 2002-04-17
WO2001002601A2 (en) 2001-01-11
WO2001002424A3 (en) 2001-07-19
WO2001002601A3 (en) 2001-07-26
WO2001002424A2 (en) 2001-01-11

Similar Documents

Publication Publication Date Title
AU5788800A (en) Peptide boronic acid inhibitors of hepatitis c virus protease
AU2001280640A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2001277967A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2055301A (en) Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
HU229997B1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
AU8063701A (en) Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
AU6371900A (en) Lactam inhibitors of hepatitis c virus ns3 protease
AU2001282922A1 (en) Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
AU2002230763A1 (en) Inhibitors of hepatitis c virus ns3 protease
AU2001245356A1 (en) Inhibitors of hepatitis c virus ns3 protease
IL155842A0 (en) Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus
AU7063598A (en) Hepatitis c ns3 protease inhibitors
AU2002230764A1 (en) Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
AU2933797A (en) Synthetic inhibitors of hepatitis c virus ns3 protease
AU2003259155A1 (en) Pharmaceutical compositions comprising hepatitis c viral protease inhibitors
HK1023779A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
AP2001002301A0 (en) Inhibition of viral infection using monovalentantigen-binding proteins
AU6111000A (en) Inhibitors of viral helcase
AU6629200A (en) Alpha-helical peptide nucleic acid alpha-pna
AU6007200A (en) Cysteine protease inhibitors
AU2108601A (en) Salicylamides as serine protease inhibitors
SI0932617T1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
AU2003277891A1 (en) Hcv ns-3 serine protease inhibitors
EP1141255A4 (en) Modified forms of hepatitis c virus ns3 protease
AU2001269092A1 (en) Inhibitors of hepatitis b virus infection

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase